1
|
Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, Bass D. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus 2020; 29:1011-1020. [PMID: 32571142 PMCID: PMC7425376 DOI: 10.1177/0961203320932219] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Objective The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). Methods A keyword-based literature search was conducted, and 26 publications were included. Results Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. Conclusions Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE.
Collapse
Affiliation(s)
| | - Justyna Amelio
- GlaxoSmithKline, Real World Evidence and Epidemiology, Stevenage, UK
| | - Kerry Gairy
- GlaxoSmithKline, Value Evidence and Outcomes, Brentford, UK
| | | | | | | | | |
Collapse
|
2
|
Okoro T, Amelio J, Mahajan A, Gupta D, Refoios Camejo R. P0857BURDEN OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN DIALYSIS AND NON-DIALYSIS-DEPENDENT PATIENTS IN EUROPE: A REVIEW OF PUBLISHED EVIDENCE. Nephrol Dial Transplant 2020. [DOI: 10.1093/ndt/gfaa142.p0857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background and Aims
Anaemia is a frequent complication in patients with chronic kidney disease (CKD). The aim of this literature review was to understand the prevalence and burden of anaemia associated with CKD, with a further focus on Europe.
Method
A targeted literature review was conducted to identify publications on prevalence estimates (search: January 2015 to August 2018), and a systematic literature review was performed to identify publications on humanistic and healthcare resource use (HRU) burden (search: from database inception to July 2018) using MEDLINE®, Embase®, Cochrane Library, and conference proceedings. These were complemented by grey literature searches. Citations were screened per predefined criteria to include observational studies and reviews. Case series/reports and conceptual model studies were excluded. The study population included patients with anaemia associated with CKD, irrespective of CKD stage, dialysis status, or modality. All searches were funded by GSK.
Results
After applying all inclusion and exclusion criteria, 18 publications were retained that contained prevalence data, of which 9 provided European data. Based on 9 publications, the prevalence of anaemia associated with CKD in European adults was reported to range from 12.8% to 61.5% (Figure). Prevalence was higher in older individuals (aged >60 years) and increased with more advanced CKD stages. However, the methodology used to identify anaemia was not consistent across studies. Anaemia was identified based on varying thresholds of haemoglobin (Hgb) levels per different clinical guidelines (Kidney Disease Improving Global Outcomes [KDIGO], N=4; World Health Organization [WHO], N=2; European Best Practice Guidelines [EBPG], N=3), use of anaemia treatment, or Hgb thresholds without a reference to a specified guideline. Most studies focused on later-stage CKD patients (3 − 5), with only 2 studies reporting rates for stage 1 and 2 patients. A total of 50 publications provided data on humanistic and HRU burden, 6 of which provided European data. The literature on humanistic and HRU burden showed adults with anaemia associated with CKD had significantly poorer health-related quality of life (HRQoL) compared with those without anaemia, with significantly lower Kidney Disease Quality of Life (KDQoL) scores reflecting poorer HRQoL observed in the following domains: symptoms/problems, effect of kidney disease, and burden of kidney disease. This finding was consistent irrespective of instrument used for HRQoL assessment. However, tools used were not specific to anaemia or anaemia associated with CKD, and publications did not mention whether thresholds for clinical meaningfulness had been identified and/or met. Publications on HRU in anaemia associated with CKD in Europe were sparse (N=1): this single published study reported increased HRU in CKD patients with anaemia compared with CKD patients without anaemia.
Conclusion
Prevalence rates of anaemia associated with CKD reported in Europe vary, with increased prevalence in later stages of CKD. Anaemia negatively impacts patient QoL and leads to increased HRU in patients with CKD. More data are needed to characterise anaemia in earlier stages of CKD and across different populations (e.g. patients with particular comorbidities or undergoing different types of dialysis) in European countries. Due to varied definitions of anaemia, it would be of interest to evaluate the extent of underdiagnosis and its impact on prevalence rates.
Collapse
Affiliation(s)
- Tony Okoro
- GSK, Value Evidence and Outcomes, Collegeville, United States of America
| | - Justyna Amelio
- GSK, Value Evidence and Outcomes, Stevenage, United Kingdom
| | | | - Digant Gupta
- Bridge Medical Consulting, Richmond, United Kingdom
| | | |
Collapse
|
3
|
Bell CF, Priest J, Stott-Miller M, Kan H, Amelio J, Song X, Limone B, Noxon V, Costenbader KH. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA. Lupus Sci Med 2020; 7:e000357. [PMID: 32341790 PMCID: PMC7174061 DOI: 10.1136/lupus-2019-000357] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 01/29/2020] [Accepted: 02/17/2020] [Indexed: 11/08/2022]
Abstract
Objective To examine the effects of belimumab initiation on healthcare resource utilisation (HCRU) and costs in SLE. Methods This retrospective observational cohort study used healthcare administrative claims data from the IBM MarketScan Commercial Claims and Encounters Database to identify patients with SLE billing codes who received ≥1 intravenous belimumab infusion between March 2011 and December 2015. The first belimumab administration was the ‘index date’. During the 6-month postindex period, nine belimumab infusions were recommended: three during the initiation period and six during the maintenance period. HCRU and cost data for inpatient admissions, emergency department visits, physician office visits, hospital-based outpatient visits, laboratory services, other outpatient services and outpatient pharmacy prescriptions were compared in the 6-month pre/postindex periods. Results Of the 1879 patients with SLE included, 43% received ≥3 intravenous initiation administrations. An average of 5.3 (SD: 2.4) of the nine recommended belimumab administrations were received within 6 months. In the 6-month preindex versus postindex periods, significant reductions were noted for inpatient hospitalisations (18% vs 9%, p<0.001; mean visits: 0.3 vs 0.14, p<0.001) and emergency department visits (40% vs 24%, p<0.001; mean visits; 3.53 vs 1.96, p<0.001). Mean total costs were higher in the 6-month postindex versus preindex period ($41 426 vs $29 270; p<0.001). Conclusions In this study of real-world intravenous belimumab for SLE, adherence to recommended infusion schedules was low. Outpatient healthcare and associated costs were higher in the 6 months after belimumab was initiated, although inpatient costs were lower. Reasons for non-adherence with belimumab and implications should be investigated.
Collapse
Affiliation(s)
- Christopher F Bell
- US Value, Evidence and Outcomes, GSK, Research Triangle Park, North Carolina, USA
| | - Julie Priest
- US Health Outcomes, ViiV Healthcare, Research Triangle Park, North Carolina, USA
| | | | - Hong Kan
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.,Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Justyna Amelio
- Epidemiology, Value Evidence and Outcomes, GSK, Stevenage, UK
| | - Xue Song
- IBM Watson Health, Cambridge, Massachusetts, USA
| | | | | | - Karen H Costenbader
- Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
4
|
Okoro T, Carroll C, Chao J, St. Laurent S, Shannon J, Clifton C, Amelio J, Dickinson H, Lindsay A. SP349ASSOCIATION OF RACE/ETHNICITY WITH ERYTHROPOIETIN STIMULATING AGENT USE AND RESISTANCE IN HEMODIALYSIS PATIENTS. Nephrol Dial Transplant 2019. [DOI: 10.1093/ndt/gfz103.sp349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Tony Okoro
- GlaxoSmithKline, Collegeville, United States of America
| | | | - Jessica Chao
- GlaxoSmithKline, Collegeville, United States of America
| | | | | | | | | | | | | |
Collapse
|
5
|
Dedman D, Coton SJ, Ghosh RE, Meeraus W, Crim C, Harvey C, Amelio J, Landis SH. Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study. Pulm Ther 2019; 5:81-95. [PMID: 32026429 PMCID: PMC6967316 DOI: 10.1007/s41030-019-0092-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Indexed: 02/06/2023] Open
Abstract
Introduction This retrospective database study explored treatment patterns and potential off-label prescribing among patients newly prescribed fluticasone furoate/vilanterol (FF/VI) in a UK primary care setting. Methods In Europe, FF/VI is approved in two strengths: 100/25 µg for adults with chronic obstructive pulmonary disease (COPD) and 100/25 µg or 200/25 µg for treatment of asthma in patients aged 12 or older. Using electronic health records from the Clinical Practice Research Datalink, new users of FF/VI or other inhaled corticosteroid/long-acting beta-agonist fixed-dose combination products were identified and classified into one of three groups: COPD diagnosis, asthma diagnosis, and other diagnosis (not COPD or asthma). Results During 2014–2015, 4373 patients initiated FF/VI: 3380 on FF/VI 100/25 (65% in the COPD diagnosis group) and 993 on FF/VI 200/25 (51% in the asthma diagnosis group). During up to 12 months of follow-up, the median number (interquartile range) of prescriptions of the index strength issued per patient was 7 (2–8) for FF/VI 100/25 and 5 (2–8) for FF/VI 200/25; most new users did not change from the index strength prescribed (93.0% COPD; 89.7% asthma, of all patients initiating treatment with FF/VI). Potential off-label FF/VI prescribing in children < 12 years old was rare (< 0.29% in the combined asthma and other diagnosis groups), and up to one in five new users of FF/VI with COPD were potentially prescribed FF/VI 200/25 off-label during the study period. Much of the potential off-label prescribing in COPD occurred in patients with a history of asthma, those presenting with greater disease severity, and/or prior treatment with high-dose steroids. Conclusions The prescription of FF/VI is rare in children under 12 years of age in the UK, according to our findings, but up to one in five COPD patients in the UK may have been prescribed FF/VI 200/25, some of which may have been off-label. Funding This study was funded by GlaxoSmithKline plc (study 205052). Study Registration GlaxoSmithKline plc Clinical Trial Registry study number 205052. Electronic supplementary material The online version of this article (10.1007/s41030-019-0092-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Daniel Dedman
- Clinical Practice Research Datalink (CPRD), Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
| | - Sonia J Coton
- Clinical Practice Research Datalink (CPRD), Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK
| | - Rebecca E Ghosh
- Clinical Practice Research Datalink (CPRD), Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK
| | - Wilhelmine Meeraus
- GlaxoSmithKline plc, Epidemiology, Value Evidence and Outcomes, Stockley Park, Uxbridge, UK
| | - Courtney Crim
- GlaxoSmithKline plc, Research and Development, Research Triangle Park, NC, USA
| | - Catherine Harvey
- GlaxoSmithKline plc, Global Clinical Safety and Pharmacovigilance, Stockley Park, Uxbridge, UK
| | - Justyna Amelio
- GlaxoSmithKline plc, Epidemiology, Value Evidence and Outcomes, Stevenage, UK
| | - Sarah H Landis
- GlaxoSmithKline plc, Epidemiology, Value Evidence and Outcomes, Stockley Park, Uxbridge, UK
| |
Collapse
|
6
|
Cronin-Fenton D, Kjærsgaard A, Nørgaard M, Amelio J, Liede A, Hernandez RK, Sørensen HT. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat 2017; 167:517-528. [PMID: 28948396 DOI: 10.1007/s10549-017-4510-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 09/12/2017] [Indexed: 10/18/2022]
Abstract
PURPOSE We developed and validated algorithms to identify metastases and breast cancer recurrence in Danish medical registries. We computed the incidence rate (IR) and hazard ratios (HRs) to evaluate predictors of these outcomes in stage II/III breast cancer patients. METHODS We included all women in Denmark diagnosed during 1999-2011 with regional or stage II/III breast cancer. Demographic, tumor, and treatment data were ascertained from population-based health registries. To facilitate diagnostic work-up of the primary cancer, follow-up began 180 days after diagnosis and continued until recurrence/metastases, death, or 31 December 2012, whichever occurred first. We computed the positive predictive values (PPVs) of recurrence, bone metastases, and visceral metastases using medical records as a gold standard. We calculated the cumulative incidence, IR per 10,000 person years, and used Cox regression to compute the HRs and associated 95% confidence intervals (95% CI) for each outcome. RESULTS Among 23,478 patients, 7073 had regional stage and 16,405 had stage II/III breast cancer. The PPV for recurrence was 72.6% (95% CI 59.3, 83.3%). The PPVs for bone and visceral metastases were 92.3% (95% CI 69.3-99.2%) and 70.8% (95% CI 51.1, 85.9%), but had low sensitivity. Five-year cumulative incidence of recurrence, bone metastases, and visceral metastases were 18.4, 2.2, and 5.2%, with corresponding 5-year IRs of 540 (95% CI 524, 557), 60 (95% CI 55, 65), and 144 (95% CI 136, 152), respectively. Predictors of recurrence and metastases included age, stage, hormone receptor status, and cancer treatment. CONCLUSION Our algorithms show moderate to high PPVs for recurrence and metastases. The IRs of metastases were lower compared with other registry-based cohort studies, so may be underestimated in Danish registries.
Collapse
Affiliation(s)
- Deirdre Cronin-Fenton
- Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, 8200, Aarhus N, Denmark.
| | - Anders Kjærsgaard
- Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, 8200, Aarhus N, Denmark
| | - Mette Nørgaard
- Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, 8200, Aarhus N, Denmark
| | | | | | | | - Henrik T Sørensen
- Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, 8200, Aarhus N, Denmark
| |
Collapse
|
7
|
Liede A, Amelio J, Bennett J, Goodman H, Peters PM, Barber R, Kehler E, Michael Sprafka J. Measuring and Improving Physician Knowledge of Safety Risks Using Traditional and Online Methods in Pharmacovigilance. Pharmaceut Med 2017; 31:257-266. [PMID: 28824275 PMCID: PMC5539261 DOI: 10.1007/s40290-017-0196-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Background Traditional methods for assessing prescriber knowledge can take several years to deliver results. This study was undertaken to obtain insights into the potential for using existing online communities to educate prescribers on therapy-related safety risks. Objective The aim of this study was to describe approaches to measuring prescribers’ knowledge of safety risk (osteonecrosis of the jaw) outlined in the European Medicine Agency’s summary of product characteristics for denosumab (XGEVA®). Methods Short multiple-choice online instruments were administered as (1) a two-round cross-sectional survey fielded in January 2013–May 2015 (traditional, nine European countries, study duration: 3 years), (2) a survey targeting the online Medscape community (seven European countries, study duration: 3 weeks), and (3) a continuing medical education module with pre-/post-assessment in an online Medscape community (Medscape Education, USA). All respondents were oncologists; treated five or more patients with bone metastases from solid tumours in the previous 3 months; and prescribed denosumab within the previous 12 months. Medscape (a WebMD company, New York, NY, USA) is the leading online medical information resource, serving approximately 3 million physicians worldwide and 400,000 within Europe. Results In the traditional 29-month study, 420 (n = 210 per round; 14% of screened physicians) individuals participated. Knowledge levels exceeded 75% correct on five questions (incidence of osteonecrosis of the jaw, concomitant risk factors and prevention of osteonecrosis of the jaw during denosumab treatment, importance of ensuring oral hygiene, and care for patients who have or develop osteonecrosis of the jaw) with less awareness of optimal osteonecrosis of the jaw treatment. The Medscape survey (n = 207; 32.1% of 645 eligible) provided similar results in a 3-week post-survey launch. The Medscape Education study (n = 264) documented knowledge acquisition. Conclusions Assessments that target physicians through online platforms where they seek information about drug-related safety risks may result in increased efficiencies, informing regulators about prescribers’ knowledge of safe use within weeks rather than years. Online communities or professional societies may provide venues in which to implement knowledge-acquisition surveys tied to training/education modules that address safety topics. Electronic supplementary material The online version of this article (doi:10.1007/s40290-017-0196-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Alexander Liede
- Center for Observational Research, Amgen Inc., 1120 Veterans Blvd, ASF3, South San Francisco, CA 94080 USA
| | | | | | | | | | | | | | - J Michael Sprafka
- Center for Observational Research, Amgen Inc., Thousand Oaks, CA USA
| |
Collapse
|
8
|
Liede A, Mansfield CA, Metcalfe KA, Price MA, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat 2017. [PMID: 28624978 PMCID: PMC5543193 DOI: 10.1007/s10549-017-4332-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Purpose Unaffected women who carry BRCA1 or BRCA2 mutations face difficult choices about reducing their breast cancer risk. Understanding their treatment preferences could help us improve patient counseling and inform drug trials. The objective was to explore preferences for various risk-reducing options among women with germline BRCA1/2 mutations using a discrete-choice experiment survey and to compare expressed preferences with actual behaviors. Methods A discrete-choice experiment survey was designed wherein women choose between hypothetical treatments to reduce breast cancer risk. The hypothetical treatments were characterized by the extent of breast cancer risk reduction, treatment duration, impact on fertility, hormone levels, risk of uterine cancer, and ease and mode of administration. Data were analyzed using a random-parameters logit model. Women were also asked to express their preference between surgical and chemoprevention options and to report on their actual risk-reduction actions. Women aged 25–55 years with germline BRCA1/2 mutations who were unaffected with breast or ovarian cancer were recruited through research registries at five clinics and a patient advocacy group. Results Between January 2015 and March 2016, 622 women completed the survey. Breast cancer risk reduction was the most important consideration expressed, followed by maintaining fertility. Among the subset of women who wished to have children in future, the ability to maintain fertility was the most important factor, followed by the extent of risk reduction. Many more women said they would take a chemoprevention drug than had actually taken chemoprevention. Conclusions Women with BRCA1/2 mutations indicated strong preferences for breast cancer risk reduction and maintaining fertility. The expressed desire to have a safe chemoprevention drug available to them was not met by current chemoprevention options. Electronic supplementary material The online version of this article (doi:10.1007/s10549-017-4332-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | - Carol A Mansfield
- RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA.
| | - Kelly A Metcalfe
- Women's College Hospital, University of Toronto, Toronto, Canada
| | - Melanie A Price
- Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), School of Psychology, The University of Sydney, Sydney, Australia
| | | | | | | | - Sue Friedman
- Facing Our Risk of Cancer Empowered (FORCE) Advocacy Organization, Tampa, FL, USA
| | | | - Joshua Posner
- RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA
| | - Steven A Narod
- Women's College Hospital, University of Toronto, Toronto, Canada
| | - Geoffrey J Lindeman
- The Royal Melbourne Hospital, Parkville, Australia.,Peter MacCallum Cancer Centre, Melbourne, Australia.,The Walter & Eliza Hall Institute of Medical Research, Parkville, Australia
| | - D Gareth Evans
- Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK
| |
Collapse
|
9
|
Liede A, Evans G, Metcalfe KA, Price M, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Lindeman G, Mansfield CA. Abstract P3-08-08: Preferences for breast cancer risk reduction among BRCA1 and BRCA2 mutation carriers: A discrete choice experiment. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-08-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- A Liede
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - G Evans
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - KA Metcalfe
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - M Price
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - C Snyder
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - HT Lynch
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - S Friedman
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - J Amelio
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - J Posner
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - G Lindeman
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| | - CA Mansfield
- Amgen Inc.; University of Manchester, United Kingdom; University of Toronto, Canada; University of Sydney, Australia; Creighton University; Facing Our Risk of Cancer Empowered (FORCE); Amgen Ltd, United Kingdom; RTI Health Solutions; Royal Melbourne Hospital and Walter & Eliza Hall Institute of Medical Research, Australia
| |
Collapse
|
10
|
Brodowicz T, Niepel D, Booth E, Hernandez RK, Braileanu G, Cawkwell M, Amelio J. P1.06-018 Treatment Patterns and Clinical Practices of Advanced (Stage IV) Non-Small Cell Lung Cancer (NSCLC) in Europe - A Structured Literature Review. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Costa Svedman F, Spanopoulos D, Taylor A, Amelio J, Hansson J. Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review. J Eur Acad Dermatol Venereol 2016; 31:603-615. [DOI: 10.1111/jdv.13950] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 08/11/2016] [Indexed: 02/03/2023]
Affiliation(s)
- F. Costa Svedman
- Karolinska Institutet; Karolinska University Hospital Solna; Stockholm Sweden
| | - D. Spanopoulos
- Centre for Observational Research; Amgen Ltd; Uxbridge UK
| | - A. Taylor
- Centre for Observational Research; Amgen Ltd; Uxbridge UK
| | - J. Amelio
- Centre for Observational Research; Amgen Ltd; Uxbridge UK
| | - J. Hansson
- Karolinska Institutet; Karolinska University Hospital Solna; Stockholm Sweden
| |
Collapse
|
12
|
Harries M, Malvehy J, Lebbe C, Heron L, Amelio J, Szabo Z, Schadendorf D. Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. Eur J Cancer 2016; 60:179-89. [PMID: 27118416 DOI: 10.1016/j.ejca.2016.01.011] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Accepted: 01/15/2016] [Indexed: 10/21/2022]
Abstract
AIMS AND BACKGROUND With the recent emergence of immunotherapies and novel targeted treatments for advanced and metastatic melanoma such as selective B-Raf inhibitors and checkpoint inhibitors, the treatment landscape in Europe has changed considerably. The aim of this review was to provide an overview of current treatment pathways in Europe for the treatment of advanced melanoma, unresectable stage III-IV. METHODS A literature search of four databases was conducted to identify publications reporting on the treatment patterns of advanced and metastatic melanoma (stage III-IV) in European populations. RESULTS Seven full-text publications and two conference abstracts reported on observational studies of melanoma treatment practices in France, Italy and the United Kingdom. Treatment patterns were identified for two time periods: 2005-2009 and 2011-2012. Common treatments reported for both periods included chemotherapy with dacarbazine, fotemustine or temozolomide. The main differences between the two periods were the introduction and prescription of immunotherapy ipilimumab and targeted therapy vemurafenib between 2011 and 2012. Across the three countries studied, the types of treatments prescribed between 2005 and 2009 were relatively similar, however, with noticeable differences in the frequency and priority of administration. CONCLUSION Treatment practices for advanced melanoma vary markedly across different European countries and continue to evolve with the introduction of new therapies. The results of this review highlight a considerable evidence gap with regards to recent treatment patterns for advanced melanoma in Europe, especially post-2011 after the introduction of novel therapeutic agents, and more recently with the introduction of programmed cell death 1 inhibitors.
Collapse
Affiliation(s)
- Mark Harries
- Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UK.
| | - Josep Malvehy
- Servicio de Dermatología, Hospital Clínic de Barcelona, Catalonia, Spain
| | - Céleste Lebbe
- Assistance Publique - Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis, Dermatology Department Université Paris-Diderot, Sorbonne Paris Cité, INSERM UMR-S 976, Paris, France
| | | | | | | | - Dirk Schadendorf
- Klinik für Dermatologie, Universitätsklinikum Essen, Essen, Germany
| |
Collapse
|
13
|
Liede A, Fairchild A, Friedman S, Amelio J, Hallett DC, Mansfield CA, Metcalfe KA. Abstract P2-09-09: Risk-reducing surgery and cancer-related distress among female BRCA1 and BRCA2 mutation carriers. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-09-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Distress levels among female BRCA1 and BRCA2 mutation carriers can be similar to levels reported among breast cancer patients. However, there is a lack of data on long-term psychosocial functioning, and it is not known if uptake of risk-reducing surgery influences long-term cancer related distress in women with a BRCA mutation who are unaffected with cancer. The objective of this study was to evaluate long-term cancer-related distress in women with a BRCA mutation, and to evaluate predictors of distress, including uptake of cancer risk reducing surgery.
Methods: Female BRCA1 or BRCA2 mutation carriers, ages 25-55, and without cancer were eligible to complete the survey online. A validated instrument, Impact of Events Scale (IES)-Revised (Horowitz 1979, Weis & Marmar 1995; 0-80 overall scale), was used to assess current levels of cancer risk-related psychological distress. Respondents were recruited through the Facing Our Risk of Cancer Empowered (FORCE) advocacy organization, which includes women at high risk of breast cancer. This interim analysis is part of a larger multi-center patient preference study of BRCA mutation carriers designed to assess women's willingness to adopt hypothetical treatments to prevent breast cancer. Linear regression was used to evaluate predictors of IES distress levels.
Results: Between January and April 2015, 259 women completed the survey. The mean age of the participants was 41 years, and the mean time since receipt of genetic test results was 3.5 years (range 0-16; median 2 years). One hundred thirty-six (52%) women elected for prophylactic bilateral mastectomy (PBM), 139 (54%) elected for bilateral salpingo oophorectomy (BSO) (93 [36%] women had both surgeries), and 77 (30%) had not undergone risk-reducing surgery. The mean total IES score was 15.1 (range 0-72; median 11). Overall, 54 (21%) women reported moderate or severe cancer-related distress, and those who had undergone risk-reducing surgery reported lower perceived risk of developing breast cancer. Results to date indicate that shorter time since notification of mutation status, not having PBM (with or without BSO) (table), and not completing post-secondary education were independent predictors of higher IES distress scores.
IES severityNo prophylactic surgeryPBM onlyBSO onlyPBM and BSOn (%)77434693Subclinical27 (35)23 (54)16 (35)44 (47)Mild26 (34)13 (30)21 (46)35 (38)Moderate18 (23)5 (12)6 (13)11 (12)Severe6 (8)2 (5)3 (6)3 (3)
Conclusions: This study measured cancer-related distress in a large population of women with BRCA mutations who participate in the FORCE online support community. Higher levels of distress were associated with not having PBM and more recent genetic test disclosure. These findings are specific to a more informed community of women with high levels of understanding of cancer risk than may be seen in the clinical setting.
Citation Format: Liede A, Fairchild A, Friedman S, Amelio J, Hallett DC, Mansfield CA, Metcalfe KA. Risk-reducing surgery and cancer-related distress among female BRCA1 and BRCA2 mutation carriers. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-09.
Collapse
Affiliation(s)
- A Liede
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| | - A Fairchild
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| | - S Friedman
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| | - J Amelio
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| | - DC Hallett
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| | - CA Mansfield
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| | - KA Metcalfe
- Amgen Inc., CA; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University of Toronto, Toronto, ON, Canada; RTI Health Solutions, Research Triangle Park, NC
| |
Collapse
|
14
|
Ferrer P, Amelio J, Ballarín E, Sabaté M, Vidal X, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L. Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury. Basic Clin Pharmacol Toxicol 2016; 119:3-9. [PMID: 26707367 DOI: 10.1111/bcpt.12550] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 12/12/2015] [Indexed: 12/12/2022]
Abstract
Antibacterials are frequently associated with idiosyncratic drug-induced liver injury (DILI). The objective of this study was to estimate the risk of macrolides and amoxicillin/clavulanate (AMC) on DILI. We conducted a systematic review (SR) and meta-analysis (MA) with studies retrieved from PubMed, Cochrane Library Plus, Web of Knowledge, clinicaltrials.gov, Livertox and Toxline (1980-2014). We searched for macrolides, AMC and MeSH and synonym terms for DILI. We included all study designs except case reports/series, all population ages and studies with a placebo/non-user comparator. We summarized the evidence with a random-effects MA. Quality of the studies was appraised with a checklist developed for SR of adverse effects. Heterogeneity and publication bias were assessed with different exploratory tools. We finally included 10 (two randomized clinical trials, six case-control, one cohort and one case-population studies) and 9 (case-population excluded) articles in the SR and MA, respectively. The overall summary relative risk of DILI for macrolides was 2.85 [95% confidence interval (CI) 1.81-4.47], p < 0.0001, I(2) = 57%. Three studies were perceived to be missing in the area of low statistical significance. Year of study and selected exposure window partly explained the variability between studies. For AMC, the risk of DILI was 9.38 (95% CI 0.65-135.41) p = 0.3, I2 = 95%. In conclusion, although spontaneous reports and case series have long established an association between macrolides and AMC with acute liver injury, these SR and MA have assessed the magnitude of this association. The low incidence of DILI and the therapeutic place of these antibiotics might tilt the balance in favour of their benefits.
Collapse
Affiliation(s)
- Pili Ferrer
- Foundation Catalan Institute of Pharmacology, Barcelona, Spain
| | | | - Elena Ballarín
- Foundation Catalan Institute of Pharmacology, Barcelona, Spain.,Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain.,Department of Pharmacology, Toxicology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain
| | - Mònica Sabaté
- Foundation Catalan Institute of Pharmacology, Barcelona, Spain.,Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain.,Department of Pharmacology, Toxicology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain
| | - Xavi Vidal
- Foundation Catalan Institute of Pharmacology, Barcelona, Spain.,Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain.,Department of Pharmacology, Toxicology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain
| | - Marietta Rottenkolber
- Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians Universitaet-Muenchen, Munich, Germany
| | - Sven Schmiedl
- Philipp Klee-Institute for Clinical Pharmacology, Helios Klinik Wuppertal, Wuppertal, Germany.,Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten-Herdecke University, Witten, Germany
| | - Joan-Ramon Laporte
- Foundation Catalan Institute of Pharmacology, Barcelona, Spain.,Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain.,Department of Pharmacology, Toxicology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain
| | - Luisa Ibáñez
- Foundation Catalan Institute of Pharmacology, Barcelona, Spain.,Department of Clinical Pharmacology, University Hospital Vall d'Hebron, Barcelona, Spain.,Department of Pharmacology, Toxicology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain
| | | |
Collapse
|
15
|
Rockberg J, Bach BA, Amelio J, Hernandez RK, Sobocki P, Engellau J, Bauer HCF, Liede A. Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958. J Bone Joint Surg Am 2015; 97:1756-66. [PMID: 26537163 DOI: 10.2106/jbjs.o.00156] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND The Swedish Cancer Registry (founded in 1958) constitutes a unique resource for epidemiological studies of giant cell tumor of bone with potential for use for population-based studies of incidence over time. The aim of this study was to provide what we believe is the first modern population-based assessment of the incidence trends of giant cell tumor, a unique osteoclastogenic lytic stromal tumor with both benign and malignant histological forms, and to compare the findings with data from the same registry on osteosarcoma, a tumor that may display similar histological characteristics. METHODS Cases were identified with use of codes for pathological bone tumor (International Classification of Diseases [ICD]-7 196). Specific morphological coding distinguishes benign (PAD 741) from malignant giant cell tumor (PAD 746) and osteosarcoma (PAD 766). RESULTS During the period of 1958 to 2011, 4625 bone tumors were reported, including 505 giant cell tumors (383 benign and 122 malignant) and 1152 osteosarcomas. From 1958 to 1982 the ratio of malignant to benign giant cell tumors was 1.3, whereas from 1983 to 2011 the ratio inverted to 0.09, suggesting a change in the reporting or diagnosis of malignant or benign cases. Cases of giant cell tumor diagnosed from 1983 to 2011 displayed an age and sex distribution (median age at diagnosis, 34.0 years; 54% female) that were consistent with those in large published case series but differed from those in 1958 to 1982 (median age at diagnosis, 31.5 years; 48% female). The most current data (1983 to 2011) showed the giant cell tumor incidence in Sweden to be 1.3 per million per year, while the osteosarcoma incidence was 2.3 per million per year. CONCLUSIONS Early Swedish Cancer Registry data (1958 to 1982) revealed a higher proportion of malignant giant cell tumors than seen in large sequential case series and a distinct age and sex profile compared with more recent data (1983 to 2011). This likely represents changes in the diagnostic workup and introduction of multidisciplinary review of giant-cell-containing tumors around 1982. Recent data may reflect the impact of expert centralized biopsy and multidisciplinary case review and more comprehensive reporting of benign giant cell tumors.
Collapse
Affiliation(s)
- Julia Rockberg
- IMS Health (Pygargus), Sveavägen 155, SE-113 46, Stockholm, Sweden
| | - Bruce A Bach
- Amgen Inc., One Amgen Center Drive, MS 38-2-B, Thousand Oaks, CA 91320-1799
| | - Justyna Amelio
- Amgen Ltd, 1 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, England
| | - Rohini K Hernandez
- Amgen Inc., One Amgen Center Drive, MS 24-2-A, Thousand Oaks, CA 93120-1799
| | - Patrik Sobocki
- IMS Health (Pygargus), Sveavägen 155, SE-113 46, Stockholm, Sweden
| | | | - Henrik C F Bauer
- Karolinska Universitetssjukhuset, Solna, A2:07,171 76 Stockholm, Sweden
| | - Alexander Liede
- Center for Observational Research, Amgen, Inc., 1120 Veterans Boulevard, ASF3, South San Francisco, CA 94080. E-mail address:
| |
Collapse
|
16
|
Ferrer P, Sabaté M, Ballarín E, Rottenkolber M, Schmiedl S, Amelio J, De Abajo F, Ruigómez A, Gil M, Huerta C, Gardarsdottir H, Afonso A, Klungel O, De Groot M, Schlinger R, Reynolds R, Ibáñez L. Measuring Drug use: differences between medical records and Healthcare Utilisation Databases. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Rottenkolber M, Fischer R, Ibáñez L, Fortuny J, Reynolds R, Amelio J, Gerlach R, Tauscher M, Thürmann P, Hasford J, Schmiedl S. Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial. BMC Pulm Med 2015; 15:55. [PMID: 25943421 PMCID: PMC4428117 DOI: 10.1186/s12890-015-0051-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 04/22/2015] [Indexed: 11/14/2022] Open
Abstract
Background After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). We aim to analyse LABA- and ICS-related prescription patterns after the SMART trial in Germany. Methods Patients documented in the Bavarian Association of Statutory Health Insurance Physicians database (approximately 10.5 million people) were included if they had a diagnosis of asthma and at least one prescription of LABA and/or ICS between 2004 and 2008. Annual period prevalence rates (PPRs) were estimated and Cochrane Armitage tests were used for time trend analyses. Results Highest annual PPRs were found for budesonide and the fixed combination of salmeterol/fluticasone. The proportion of “concomitant LABA and ICS users” increased from 52.0 to 57.6% within the study period, whereas for “LABA users without ICS” a slight decrease from 6.5 to 5.4% was found. In 2008, the proportion of patients with at least one quarter with a LABA prescription without concomitant ICS was highest in elderly, male patients (≈20%). In the majority of these patients, a concomitant diagnosis of COPD (i.e. asthma-COPD overlap syndrome [ACOS]) was present. Conclusions Between 2004 and 2008, we found a moderate increase in guideline-adherent LABA prescribing in a representative German population. Elderly men received a significant number of LABA prescriptions without concomitant ICS probably due to ACOS. Electronic supplementary material The online version of this article (doi:10.1186/s12890-015-0051-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Marietta Rottenkolber
- Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Marchioninistr. 15, D-81377, Munich, Germany.
| | | | - Luisa Ibáñez
- Fundació Institut Català de Farmacologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. .,Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain.
| | | | | | | | - Roman Gerlach
- National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany.
| | - Martin Tauscher
- National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany.
| | - Petra Thürmann
- Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany. .,Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany.
| | - Joerg Hasford
- Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Marchioninistr. 15, D-81377, Munich, Germany.
| | - Sven Schmiedl
- Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany. .,Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany.
| |
Collapse
|
18
|
Amelio J, Sandberg J, Hernandez R, Sobocki P, Stryker S, Engellau J, Bach B, Liede A. Population-Based Study of Giant Cell Tumour of the Bone in Sweden. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Liede A, Sandberg J, Amelio J, Hernandez R, Sobocki P, Bauer H, Bach B, Engellau J. Trends in Giant Cell Tumour of the Bone and Osteosarcoma Incidence in the Sweden (1958-2011). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Ferrer P, Ballarín E, Sabaté M, Vidal X, Rottenkolber M, Amelio J, Hasford J, Schmiedl S, Ibáñez L. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology 2014; 42:107-20. [PMID: 24401764 DOI: 10.1159/000356807] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Accepted: 10/29/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Since the FDA (Food and Drug Administration) report on antiepileptic drugs (AEDs) and suicide risk was released (2008), several studies have been published on this controversial relationship. This systematic review (SR) gives an updated approach to this health issue. SUMMARY We searched 6 databases. We ultimately included 11 publications: 4 cohort studies, 1 case-crossover study, 2 community case-control studies, and 4 SRs. Overall, 1 SR described studies already included; 3 studies reported a 2- to 4-fold overall increase in risk; 1 study reported an increased risk of suicide among epilepsy patients on AEDs with high risk of depression; 1study showed a protective effect among epilepsy patients; 2 studies were conducted with patients with bipolar disorder (1 showed a protective effect, whereas the other showed a 3-fold increase in risk of suicide), and the other 3 studies reported results for single AEDs. Several biases affected the published results. KEY MESSAGES There is no clear evidence of an association between the use of AEDs and an increased risk of suicide because of the heterogeneity in the studies at the clinical and methodological level. A future study should cover all indications for use, retrieve information from a healthcare database, and include a defined set of covariates to avoid bias.
Collapse
Affiliation(s)
- Pili Ferrer
- Fundació Institut Català de Farmacologia, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
In the present study, we used a spatial cuing paradigm in conjunction with a choice identification task to investigate whether exogenous attentional orienting and inhibition of return are affected by attentional control settings. As in previous studies (e.g., Folk, Remington, & Johnston, 1992), onset- and color-defined targets were crossed with uninformative onset- and color-defined cues. As expected, when the cue-target stimulus onset asynchrony (SOA) was short (i.e., 100 msec), the results showed that exogenous attentional orienting was contingent on attentional set; attentional capture occurred in response to a particular cue only when the feature that defined the cue also defined the target (Folk et al., 1992). More importantly, when the cue-target SOA was long (i.e., 1,000 msec), the results showed that the occurrence of inhibition of return was also contingent on attentional set, at least partially so; inhibition of return occurred in response to onset cues only when they preceded onset targets. In contrast, inhibition of return never occurred in response to color cues (at a variety of long SOAs). The associations and dissociations that were observed between exogenous attentional orienting and inhibition of return are discussed in terms of posterior and anterior attention networks in the brain (Posner & Petersen, 1990).
Collapse
Affiliation(s)
- B S Gibson
- Department of Psychology, University of Notre Dame, IN 46556, USA.
| | | |
Collapse
|